Related Experiment Video

Updated: Sep 1, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer

Michela Cortesi1, Michele Zanoni1, Roberta Maltoni2

  • 1Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Expert Opinion on Therapeutic Targets
|August 13, 2022
PubMed
Abstract

Insights

New antibody-drug conjugates targeting Trop2 show promise for treating triple-negative breast cancer (TNBC), a subtype with poor prognosis. Research explores Trop2 as a therapeutic target to improve outcomes for breast cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Breast cancer (BC) is a leading cause of cancer death in women, with triple-negative breast cancer (TNBC) having the poorest prognosis.
  • High metastatic potential and aggressiveness of TNBC necessitate novel therapeutic targets.
  • Trop2, a transmembrane glycoprotein involved in calcium signaling, is an emerging target in epithelial cancers, especially breast cancer.

Purpose of the Study:

  • To review the structure and function of Trop2.
  • To summarize therapeutic strategies targeting Trop2 in cancer.
  • To evaluate the efficacy and potential of Trop2-targeting antibody-drug conjugates (ADCs) in breast cancer, particularly TNBC.

Main Methods:

  • Literature review of Trop2 structure, function, and therapeutic targeting.
  • Analysis of recent clinical data and FDA approvals for Trop2-targeted ADCs.
  • Discussion of future prospects and challenges for Trop2-targeted therapies in various breast cancer subtypes.

Main Results:

  • Trop2-targeted ADCs have received accelerated FDA approval for metastatic TNBC therapy.
  • ADCs represent the most successful strategy for targeting Trop2 currently.
  • Trop2's role in cancer progression and its potential as a therapeutic target are highlighted.

Conclusions:

  • Trop2-targeted ADCs offer a promising new avenue for treating metastatic TNBC.
  • Further research is needed to explore the efficacy of these ADCs in other breast cancer subtypes.
  • Understanding Trop2's structure and function is crucial for optimizing therapeutic strategies and overcoming potential pitfalls.
Keywords:
Breast cancerSacituzumab GovitecanTrop2therapeutic target

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K